Loading
The US government already runs a small programme that turns academic cancer discoveries into drugs ready for human trials. Scale it up tenfold and copy it in other countries.
NCI's Experimental Therapeutics (NExT) programme and the Cancer Research UK Centre for Drug Development show that public bodies can run medicinal chemistry, pharmacology and IND-enabling work on academic targets and then license candidates to companies. Both are small relative to the pipeline of stranded academic discoveries. The proposal is to expand these to tens of concurrent programmes each, prioritising undruggable and neglected targets, with explicit licensing-out at phase 1 or 2 and revenue returning to the programme. Public development is also the natural home for assets with no commercial sponsor (rare cancers, generics, combinations of competitors' drugs).
Shares The Institute of Cancer Research, The undruggable drivers, Cancer Research UK.
Shares The Institute of Cancer Research, The valley of death between lab and product, Cancer Research UK.
Shares The valley of death between lab and product, Cancer Research UK, National Cancer Institute (NIH).
Shares Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product, National Cancer Institute (NIH).
Shares A non-profit pharmaceutical company for the cancers markets ignore, The valley of death between lab and product.
Shares The Institute of Cancer Research, Cancer Research UK.
Shares Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product.
Shares Regional translational institutes with academic GMP suites and IND teams, The valley of death between lab and product.